Literature DB >> 16896801

Enhancement of vascular smooth muscle cell migration by urotensin II.

Satoshi Matsusaka1, Ichiro Wakabayashi.   

Abstract

The effects of urotensin II (UII) on migration of human aortic smooth muscle cells (HASMCs) were investigated. UII (1-100 nM) significantly increased velocity of HASMC motility in a concentration-dependent manner. Stress-fiber formation and ERK (p44/p42) activity were also increased by UII. U0126 and PD 98059, MEK inhibitors, abolished the effects of UII on motility velocity and stress-fiber formation. These results suggest that UII enhances HASMC migration through activation of an ERK-dependent pathway.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16896801     DOI： 10.1007/s00210-006-0086-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


  18 in total

1.  Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation.

Authors:  T Watanabe; R Pakala; T Katagiri; C R Benedict
Journal:  J Hypertens       Date:  2001-12       Impact factor: 4.844

Review 2.  Cardiovascular actions of human urotensin II--considerations for hypertension.

Authors:  Fraser D Russell; Peter Molenaar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

3.  Increase of smooth muscle cell migration and of intimal hyperplasia in mice lacking the alpha/beta hydrolase domain containing 2 gene.

Authors:  Keishi Miyata; Yuichi Oike; Takayuki Hoshii; Hiromitsu Maekawa; Hisao Ogawa; Toshio Suda; Kimi Araki; Ken-ichi Yamamura
Journal:  Biochem Biophys Res Commun       Date:  2005-04-01       Impact factor: 3.575

4.  Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.

Authors:  Wei Song; John McDonald; Valeria Camarda; Girolamo Calo; Remo Guerrini; Erika Marzola; Jonathan P Thompson; David J Rowbotham; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-05       Impact factor: 3.000

5.  Expression of urotensin-II in human coronary atherosclerosis.

Authors:  Ghada S Hassan; Stephen A Douglas; Eliot H Ohlstein; Adel Giaid
Journal:  Peptides       Date:  2005-07-18       Impact factor: 3.750

6.  Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats.

Authors:  Y Zou; R Nagai; T Yamazaki
Journal:  FEBS Lett       Date:  2001-11-09       Impact factor: 4.124

Review 7.  Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

Authors:  S A Douglas; E H Ohlstein
Journal:  Trends Cardiovasc Med       Date:  2000-08       Impact factor: 6.677

8.  Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling.

Authors:  Kazuhiko Tamura; Masahiro Okazaki; Masahito Tamura; Kazuhiko Isozumi; Hiromi Tasaki; Yasuhide Nakashima
Journal:  Life Sci       Date:  2003-01-17       Impact factor: 5.037

9.  Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1.

Authors:  Mika Matsushita; Masayoshi Shichiri; Nozomi Fukai; Naoko Ozawa; Takanobu Yoshimoto; Nobuyuki Takasu; Yukio Hirata
Journal:  Endocrinology       Date:  2003-05       Impact factor: 4.736

10.  Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines.

Authors:  Patrick Ziltener; Célia Mueller; Bénédicte Haenig; Michael W Scherz; Oliver Nayler
Journal:  J Recept Signal Transduct Res       Date:  2002 Feb-Nov       Impact factor: 2.092
View more
  13 in total

1.  Urotensin upregulates transforming growth factor-β1 expression of asthma airway through ERK-dependent pathway.

Authors:  Wei-Xi Zhang; Ya-Feng Liang; Xiao-Ming Wang; Ying Nie; Lei Chong; Li Lin; Chun Chen; Chang-Chong Li
Journal:  Mol Cell Biochem       Date:  2012-01-21       Impact factor: 3.396

2.  Intra-ventral tegmental area microinjections of urotensin II modulate the effects of cocaine.

Authors:  L E Mueller; M A Kausch; T Markovic; D A A MacLaren; D M Dietz; J Park; S D Clark
Journal:  Behav Brain Res       Date:  2014-10-01       Impact factor: 3.332

3.  Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma.

Authors:  C Lecointre; L Desrues; J E Joubert; N Perzo; P-O Guichet; V Le Joncour; C Brulé; M Chabbert; R Leduc; L Prézeau; A Laquerrière; F Proust; P Gandolfo; F Morin; H Castel
Journal:  Oncogene       Date:  2015-01-19       Impact factor: 9.867

4.  The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy.

Authors:  K S Oh; J H Lee; K Y Yi; C J Lim; S Lee; C H Park; H W Seo; B H Lee
Journal:  Br J Pharmacol       Date:  2015-03-26       Impact factor: 8.739

5.  Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells.

Authors:  Myriam Iglewski; Stephen R Grant
Journal:  Vasc Health Risk Manag       Date:  2010-09-07

6.  Effects of urotensin II and its specific receptor antagonist urantide on rat vascular smooth muscle cells.

Authors:  Juan Zhao; Shu-Feng Zhang; Yan Shi; Li-Qun Ren
Journal:  Bosn J Basic Med Sci       Date:  2013-05       Impact factor: 3.363

7.  The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats.

Authors:  Juan Zhao; Quan-Xin Yu; Wei Kong; Hai-Cheng Gao; Bo Sun; Ya-Qin Xie; Li-Qun Ren
Journal:  Exp Ther Med       Date:  2013-04-09       Impact factor: 2.447

8.  Urantide improves atherosclerosis by controlling C-reactive protein, monocyte chemotactic protein-1 and transforming growth factor-β expression in rats.

Authors:  Juan Zhao; Li-DE Xie; Cheng-Jun Song; Xiao-Xia Mao; Hai-Rong Yu; Quan-Xin Yu; Li-Qun Ren; Yan Shi; Ya-Qin Xie; Ying Li; Sha-Sha Liu; Xiao-Hong Yang
Journal:  Exp Ther Med       Date:  2014-03-31       Impact factor: 2.447

9.  DUX4 differentially regulates transcriptomes of human rhabdomyosarcoma and mouse C2C12 cells.

Authors:  Vishakha Sharma; Naoe Harafuji; Alexandra Belayew; Yi-Wen Chen
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

10.  Moxibustion Inhibits the ERK Signaling Pathway and Intestinal Fibrosis in Rats with Crohn's Disease.

Authors:  Xiaomei Wang; Yuan Lu; Luyi Wu; Chen Zhao; Chunbin Song; Shuguang Yu; Baixiao Zhao; Tianping Zhao; Huirong Liu; Chuanzi Dou; Yingying Zhang; Huangan Wu
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-22       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.